|
1
|
Gryczyńska M: Thyroid cancer-principles in
diagnosis and treatment according to current Recommendations of
Polish Group in the matter of Neuroendocrine Tumours. Adv Head Neck
Surg. 1:3–17. 2007.
|
|
2
|
Wojciechowska U, Dzidkowska J and Zatoński
W: Cancer in Poland in 2010 - Cancer Registration. Polish National
Cancer Control Programme; Warszawa, Poland: 2012
|
|
3
|
Schlumberger M and Pacini F: Pathology of
thyroid tumors. Thyroid Tumors. 2nd edition. Editions Nucléon;
Paris: pp. 35–47. 2003
|
|
4
|
Harach HR and Ceballos GA: Thyroid cancer,
thyroiditis and dietary iodine: a review based on the Salta,
Argentina model. Endocr Pathol. 19:209–220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eszlinger M, Krogdahl A, Münz S, et al:
Impact of molecular screening for point mutations and
rearrangements in routine air-dried fine-needle aspiration samples
of thyroid nodules. Thyroid. 24:305–313. 2014. View Article : Google Scholar
|
|
6
|
Kabat GC, Kim MY, Wactawski-Wende J, et
al: Menstrual and reproductive factors, exogenous hormone use, and
risk of thyroid carcinoma in postmenopausal women. Cancer Causes
Control. 23:2031–2040. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leux C, Truong T, Petit C,
Baron-Dubourdieu D and Guénel P: Family history of malignant and
benign thyroid diseases and risk of thyroid cancer: a
population-based case-control study in New Caledonia. Cancer Causes
Control. 23:745–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cooper DS, Doherty GM, Haugen BR, et al:
Revised American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang S, Wuu J, Savas L, Patwardhan N and
Khan A: The role of cell cycle regulatory proteins, cyclin D1,
cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol.
29:1304–1309. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motokura T, Bloom T, Kim HG, et al: A
novel cyclin encoded by a bcl1-linked candidate oncogene. Nature.
350:512–515. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Knudsen KE, Diehl JA, Haiman CA and
Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer
risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Institute of Human Genetics. http://ihg.gsf.de/ihg/snps.html.
Accessed November 15, 2013
|
|
13
|
Barrett JC, Fry B, Maller J and Daly MJ:
Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics. 21:263–265. 2005. View Article : Google Scholar
|
|
14
|
dbSNP database. http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9344.
Accessed September 1, 2013
|
|
15
|
Borun P, Jerzy S, Ziemnicka K, et al:
Absence of the RET+3:T allele in the MTC patients. Hered Cancer
Clin Pract. 10:142012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gracia-Aznarez FJ, Fernandez V, Pita G, et
al: Whole exome sequencing suggests much of non-BRCA1/BRCA2
familial breast cancer is due to moderate and low penetrance
susceptibility alleles. PLoS One. 8:e556812013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen B, Cao L, Yang P, et al: Cyclin D1
(CCND1) G870A gene polymorphism is an ethnicity-dependent risk
factor for digestive tract cancers: A meta-analysis comprising
20,271 subjects. Cancer Epidemiol. 36:106–115. 2012. View Article : Google Scholar
|
|
18
|
Li Z, Jiao X, Wang C, et al: Alternative
cyclin D1 splice forms differentially regulate the DNA damage
response. Cancer Res. 70:8802–8811. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou C, An H, Hu M, et al: The cyclin D1
(CCND1) G870A polymorphism and lung cancer susceptibility: a
meta-analysis. Tumour Biol. 34:3831–3837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui J, Shen L and Wang Y: Specific CCND1
G870A alleles associated with breast cancer susceptibility: a
meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer
Prev. 13:5023–5025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Absenger G, Benhaim L, Szkandera J, et al:
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical
outcome in colon cancer patients treated with adjuvant 5-FU-based
chemotherapy. Pharmacogenomics J. 14:130–134. 2014. View Article : Google Scholar
|
|
22
|
Sanyal S, Festa F, Sakano S, et al:
Polymorphisms in DNA repair and metabolic genes in bladder cancer.
Carcinogenesis. 25:729–734. 2004. View Article : Google Scholar
|
|
23
|
Simpson DJ, Fryer AA, Grossman AB, et al:
Cyclin D1 (CCND1) genotype is associated with tumour grade in
sporadic pituitary adenomas. Carcinogenesis. 22:1801–1807. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Warchoł T, Kruszyna L, Lianeri M, Roszak A
and Jagodziński PP: Distribution of CCND1 A870G polymorphism in
patients with advanced uterine cervical carcinoma. Pathol Oncol
Res. 17:133–137. 2011. View Article : Google Scholar
|
|
25
|
Tsai MH, Tsai CW, Tsou YA, et al:
Significant association of cyclin D1 single nucleotide
polymorphisms with oral cancer in Taiwan. Anticancer Res.
31:227–231. 2011.PubMed/NCBI
|
|
26
|
Goode EL, Fridley BL, Vierkant RA, et al:
Candidate gene analysis using imputed genotypes: cell cycle SNPs
and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev.
18:935–944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Driver KE, Song H, Lesueur F, et al:
Association of single-nucleotide polymorphisms in the cell cycle
genes with breast cancer in the British population. Carcinogenesis.
29:333–341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bonilla C, Lefèvre JH, Winney B, et al:
Cyclin D1 rare variants in UK multiple adenoma and early-onset
colorectal cancer patients. J Hum Genet. 56:58–63. 2011. View Article : Google Scholar
|
|
29
|
National Center for Biotechnology
Information. http://www.ncbi.nlm.nih.gov/projects/SNPsnp_ref.cgi?rs=3862792.
Accessed September 1, 2013
|
